Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pronova BioPharma
Oslo, Norwayomega3.basf.com ↗
- Ownership
- Private
- Employees
- ~47
- Development stage
- Other
01
Overview
Pronova BioPharma developed and commercialized Omacor/Lovaza, a prescription omega‑3 fatty acid product approved in the US, Europe, and Asia for lowering triglyceride levels. The drug has demonstrated efficacy as both monotherapy and in combination with statins for cardiovascular risk reduction. At its peak, global sales exceeded $700 million annually[2][3].
- Therapeutic areas
- CardiovascularMetabolic Disorders
- Modalities
- Omega-3 fatty acids (marine-derived APIs)
- Industry
- Biotech
02
Partnerships
GlaxoSmithKline (US marketing/distribution)[2][3]Takeda Pharmaceutical Co. Ltd. (Japan)[2][3]Solvay/Abbott Laboratories (UK/Germany)[2][3]Prospa S.p.A. (Italy)[2]Kuhnil Pharmaceutical Co., Ltd.[3]Pierre Fabre, Ferrer, SPA[3]
Beyond the preview
Go deeper on Pronova BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pronova BioPharma.